General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT06608927

Background Information

To evaluate the OS of quemliclustat versus placebo when each is given in combination with SOC NP-Gem i patients with confirmed mPDAC.

For more information, visit: https://clinicaltrials.gov/study/NCT06608927

Offered At

Inova Schar Cancer Institute
A division of Inova Fairfax Hospital
8081 Innovation Park Drive 
Fairfax, VA 22031
Principal Investigator

Timothy Cannon, MD 

Eligibility Information

  • Age greater or equal to 18 years (or greater than or equal to regionally approved age of consent of participation in investigational clinical studies) at the time of signing the informed consent
  • Have histologically or cytologically confirmed PDAC that is metastatic
  • At least 1 target lesion measurable by computed tomography (CT)/magnetic resonance imaging (MRI) per RECIST v1.1. not within a field of prior radiation therapy

Ineligibility Information

  • Previously treated for locally advanced, unresectable PDAC
  • History of brain metastases or leptomeningeal metastases
  • Prior treatment with a CD73 antagonist or inhibitor